First-of-its-kind money-back program instituted
Under the plan, individuals with a detectable viral load following treatment with telbivudine for six months will be reimbursed for out-of-pocket costs.
Adults with chronic hepatitis B who have been treated with telbivudine (Tyzeka, Novartis) tablets for six months may be eligible to participate in Novartis' Six-Month Money-Back Commitment Program. Under the plan, individuals with a detectable viral load following treatment with telbivudine for six months will be reimbursed for out-of-pocket costs. One study has shown that telbivudine reduced hepatitis B virus to undetectable levels at six months in 44% of hepatitis B e-antigen positive patients and 80% of e-antigen negative patients. Participants can enroll by completing the Patient Support Enrollment Card, which is part of the Tyzeka Patient Starter Kit. Telbivudine is indicated for the treatment of chronic hepatitis B in adults with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases or histologically active disease.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
